logo
logo
AI

Discover the World’s Fastest Business Insights

Get real-time alerts on funding rounds, executive hires, acquisitions, and more— plus verified contact details and AI-powered outreach to connect faster.
Sign up now to unlock exclusive data and opportunities.

Grapheal Raises EUR1.9 Million to Advance Development of Embedded Biosensing Technology and Application in Digital COVID Testing and Wound Monitoring

Grapheal Raises EUR1.9 Million to Advance Development of Embedded Biosensing Technology and Application in Digital COVID Testing and Wound Monitoring

02/09/21, 12:35 PM
Location
https://purecatamphetamine.github.io/country-flag-icons/3x2/FR.svggrenoble
Grapheal, a developer of graphene-based embedded biosensors for on-site diagnostics and remote patient monitoring, announced today that it has raised a total of EUR1.9 million in equity and non-dilutive sources, including seed financing from Novalis Biotech’s Acceleration Fund, several innovation grants, and Bpifrance convertible notes and loans.

Company Info

Company
Novalis Biotech
Location
grenoble, auvergne rhône alpes, france
Additional Info
Novalis Biotech (Ghent, Belgium) is an early stage venture capital investor in technologies that revolutionize healthcare. The company’s core competence lies in digitalization in the life sciences with a focus on bioinformatics, genomics and diagnostics. Novalis strongly believes in applying innovative enabling technology to advance the prevention, diagnosis, or treatment of a disease. Novalis Biotech Acceleration (Fund II) announced the first closing in November 2020.
G2 High Performer Badge

Never Miss an Opportunity: Your #1 Sales Intelligence Tool

Get lightning-fast updates on funding rounds, executive hires, contract awards, and more—powered by AI-driven insights to help you connect with the right prospects first.